MPLT Key Statistics, Chart & Performance
The current stock price of MPLT is 19 USD. In the past month the price increased by 14.56%.
MPLT Latest News, Press Relases and Analysis
MPLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 14.8 | 174.28B | ||
| GILD | GILEAD SCIENCES INC | 14.77 | 150.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.94 | 114.26B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.72 | 74.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 862.76 | 58.13B | ||
| INSM | INSMED INC | N/A | 43.43B | ||
| NTRA | NATERA INC | N/A | 33.82B | ||
| BIIB | BIOGEN INC | 10.74 | 26.38B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.27 | 20.76B | ||
| INCY | INCYTE CORP | 14.98 | 18.88B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About MPLT
Company Profile
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
Company Info
MAPLIGHT THERAPEUTICS INC
800 Chesapeake Drive
Redwood City CALIFORNIA US
Employees: 0
Phone: 16508394360
MAPLIGHT THERAPEUTICS INC / MPLT FAQ
What does MPLT do?
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. The company is headquartered in Redwood City, California. The company went IPO on 2025-10-27. The firm is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. The company is also advancing two preclinical programs, ML-021 and ML-009.
What is the current price of MPLT stock?
The current stock price of MPLT is 19 USD. The price increased by 2.76% in the last trading session.
Does MAPLIGHT THERAPEUTICS INC pay dividends?
MPLT does not pay a dividend.
What is the ChartMill technical and fundamental rating of MPLT stock?
MPLT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of MAPLIGHT THERAPEUTICS INC (MPLT)?
MAPLIGHT THERAPEUTICS INC (MPLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.13).
Can you provide the market cap for MAPLIGHT THERAPEUTICS INC?
MAPLIGHT THERAPEUTICS INC (MPLT) has a market capitalization of 829.16M USD. This makes MPLT a Small Cap stock.
MPLT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MPLT.
MPLT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MPLT. While MPLT has a great health rating, there are worries on its profitability.
MPLT Financial Highlights
Over the last trailing twelve months MPLT reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS decreased by -39.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -154.27% | ||
| ROE | -203.52% | ||
| Debt/Equity | 0 |
MPLT Forecast & Estimates
9 analysts have analysed MPLT and the average price target is 31.62 USD. This implies a price increase of 66.42% is expected in the next year compared to the current price of 19.